These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 23473682

  • 1. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.
    Cui J, Fu R, Zhou LH, Chen SP, Li GW, Qian SX, Liu S.
    Bioorg Med Chem Lett; 2013 Apr 15; 23(8):2442-50. PubMed ID: 23473682
    [Abstract] [Full Text] [Related]

  • 2. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR, Kumar LG, K P, Nair SV, K M, C GM.
    J Biomol Struct Dyn; 2019 Nov 15; 37(18):4747-4766. PubMed ID: 30580670
    [Abstract] [Full Text] [Related]

  • 3. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
    Vrontaki E, Melagraki G, Voskou S, Phylactides MS, Mavromoustakos T, Kleanthous M, Afantitis A.
    Mini Rev Med Chem; 2017 Nov 15; 17(3):188-204. PubMed ID: 28143387
    [Abstract] [Full Text] [Related]

  • 4. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
    Shukla S, Kouanda A, Silverton L, Talele TT, Ambudkar SV.
    Mol Pharm; 2014 Jul 07; 11(7):2313-22. PubMed ID: 24865254
    [Abstract] [Full Text] [Related]

  • 5. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
    Dhanachandra Singh Kh, Karthikeyan M, Kirubakaran P, Nagamani S.
    J Mol Graph Model; 2011 Sep 07; 30():186-97. PubMed ID: 21831680
    [Abstract] [Full Text] [Related]

  • 6. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
    San Juan AA.
    J Mol Graph Model; 2007 Sep 07; 26(2):482-93. PubMed ID: 17446106
    [Abstract] [Full Text] [Related]

  • 7. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T.
    Bioorg Med Chem Lett; 2006 Mar 01; 16(5):1421-5. PubMed ID: 16332440
    [Abstract] [Full Text] [Related]

  • 8. Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib.
    Pan X, Dong J, Shao R, Su P, Shi Y, Wang J, He L.
    Bioorg Med Chem Lett; 2015 Oct 01; 25(19):4164-8. PubMed ID: 26298495
    [Abstract] [Full Text] [Related]

  • 9. Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors.
    Bhatt HG, Patel PK.
    Bioorg Med Chem Lett; 2012 Jun 01; 22(11):3758-65. PubMed ID: 22546667
    [Abstract] [Full Text] [Related]

  • 10. Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors.
    Teli MK, Rajanikant GK.
    J Enzyme Inhib Med Chem; 2012 Aug 01; 27(4):558-70. PubMed ID: 21851209
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors.
    Pan X, Dong J, Gao H, Wang F, Zhang Y, Wang S, Zhang J.
    Chem Biol Drug Des; 2014 May 01; 83(5):592-9. PubMed ID: 24330598
    [Abstract] [Full Text] [Related]

  • 12. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
    Falchi F, Manetti F, Carraro F, Naldini A, Maga G, Crespan E, Schenone S, Bruno O, Brullo C, Botta M.
    ChemMedChem; 2009 Jun 01; 4(6):976-87. PubMed ID: 19326384
    [Abstract] [Full Text] [Related]

  • 13. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ, Manley PW.
    Curr Opin Cell Biol; 2009 Apr 01; 21(2):288-95. PubMed ID: 19217274
    [Abstract] [Full Text] [Related]

  • 14. 3D-QSAR studies of some tetrasubstituted pyrazoles as COX-II inhibitors.
    Gupta GK, Kumar A.
    Acta Pol Pharm; 2012 Apr 01; 69(4):763-72. PubMed ID: 22876620
    [Abstract] [Full Text] [Related]

  • 15. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC, Lin CY, Chi HC, Hwang CS, Chen TS, Tang CY, Hsiao NW.
    J Chem Inf Model; 2012 Jan 23; 52(1):146-55. PubMed ID: 22142286
    [Abstract] [Full Text] [Related]

  • 16. The background, discovery and clinical development of BCR-ABL inhibitors.
    Lambert GK, Duhme-Klair AK, Morgan T, Ramjee MK.
    Drug Discov Today; 2013 Oct 23; 18(19-20):992-1000. PubMed ID: 23769978
    [Abstract] [Full Text] [Related]

  • 17. Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors.
    Reddy KK, Singh SK, Dessalew N, Tripathi SK, Selvaraj C.
    J Enzyme Inhib Med Chem; 2012 Jun 23; 27(3):339-47. PubMed ID: 21699459
    [Abstract] [Full Text] [Related]

  • 18. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T, Commodore L, Huang WS, Wang Y, Sawyer TK, Shakespeare WC, Clackson T, Zhu X, Dalgarno DC.
    Chem Biol Drug Des; 2010 Jan 23; 75(1):18-28. PubMed ID: 19895503
    [Abstract] [Full Text] [Related]

  • 19. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K, Lindner M, Pianwanit S, Kokpol S, Sippl W.
    Eur J Med Chem; 2009 Apr 23; 44(4):1383-95. PubMed ID: 18976834
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Lü S, Luo Q, Hao X, Li X, Ji L, Zheng W, Wang F.
    Bioorg Med Chem Lett; 2011 Dec 01; 21(23):6964-8. PubMed ID: 22033461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.